Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 1, 2015
Pharmacy Choice - News - Generic Drugs - July 1, 2015

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 47     Next >>     Go To Page:

7/1/15 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; General Licensing Provisions;...
All comments should be identified with the OMB control number 0910-0719. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. The Patient Protection and...
7/1/15 - Corporate Reputation of Pharma in 2014 - a Perspective of Patient Groups with an Interest in Neurological Conditions - 2015 Edition
By a News Reporter-Staff News Editor at Biotech Week Research and Markets has announced the addition of the "Corporate Reputation of Pharma in 2014- a Perspective of Patient Groups with an Interest in Neurological Conditions- 2nd Edition" report to their offering. The increase is also due to the fact that the company rankings had slid previously
7/1/15 - Federal Agencies Outline 23 Information Collection Options
WASHINGTON, July 1 The Federal Register issued the following information collection from federal agencies:. -Census Bureau: Manufacturers' Unfilled Orders Survey. The Bureau of Economic Analysis, the Counsel of Economic Advisors, the Federal Reserve Board, the Conference Board, and members of the business community such as the National Associatio
7/1/15 - Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case
According to an Order issued in the U.S. District Court, Southern District of West Virginia on June 26th, the Court rejected the Plaintiff's assertion that one manufacturer can be held liable for injuries stemming from another manufacturer's product. Because of FDA regulations governing generic drug labels, they are pre-empted from bringing certain
7/1/15 - Marksans Pharma Acquires Time-Cap Lab
Deal Type: Acquisition Deal Sub Type: 100% Acquisition Deal Country: United States of America Deal Status: Completed Deal Value: 0.0000 USD. Marksans Pharma Ltd., a pharmaceutical company engaged in research, manufacturing and marketing of generic pharmaceutical formulation, through its wholly owned subsidiary Marksans Pharma Inc., has acquired 100
7/1/15 - RNCOS - Business Consultancy Services: Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars
With a slew of major biologic blockbuster drugs up for patent expiry in the coming years, players involved in biosimilar production are leaving no stone unturned to cash in on the opportunity. A new research study conducted by RNCOS, "Global Biosimilar Market Outlook 2020", reveals that the market, which was worth US$ 1.89 Billion in 2014, is expec
7/1/15 - Tennessee State Representative Sexton Honored as BIO State Legislator of the Year
By a News Reporter-Staff News Editor at Biotech Week The Biotechnology Industry Organization announced its selection of Tennessee State Representative Cameron Sexton as a state Legislator of the Year for 2015. Rep. Sexton, as Chairman of the Tennessee House Health Committee, sponsored and passed the Tennessee Affordable Drug Act, which authorized
7/1/15 - Teva Launches Generic Aggrenox Capsules in the United States
Teva Pharmaceutical Industries Ltd., today announced the launch of generic Aggrenox capsules in the United States. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot. Teva recognizes the devastating impact of a stroke and is pleased to launch
7/1/15 - The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs)
Lupin, Strides, HEC Group, Huahai Bring Total Number of MPP Sub-licensees to Fourteen Companies. New companies Lupin and Strides Arcolab recently signed agreements to produce dolutegravir, a promising new HIV medicine the MPP licensed from ViiV Healthcare two months after its approval in Europe. The agreements follow MPP's June 9 announcement of...
7/1/15 - Unified prescription form is launched [The Daily Star, Beirut, Lebanon]
July 01 BEIRUT The unified prescription form, which makes it easier for Lebanese patients to access inexpensive medicine, was launched Tuesday in what Prime Minister Tammam Salam called a "great national achievement." According to Health Minister Wael Abu Faour, generic drugs comprise just 13 percent of the pharmaceutical market in Lebanon.
6/30/15 - Global Anti-Bacterial Drugs Market Assessment & Forecast 2015-2019
Dublin- Research and Markets has announced the addition of the "Global Anti-Bacterial Drugs Market Assessment& Forecast: 2015-2019" report to their offering. The majority can be attributed to large volume generic sales as well as a strongest innovative R&D activity in the sector with a large number of companies such as Cubist Pharmaceuticals, Cempr
6/30/15 - Hikma Pharma, Mallinckrodt Bid For Boehringer's Roxane Labs : Bloomberg
LONDON- Hikma Pharmaceuticals Plc. is among bidders for Boehringer Ingelheim GmbH's Roxane Labs business in the U.S., Bloomberg reported citing people familiar with the matter. The report said that other potential buyers for the generic pharmaceutical unit, which may fetch as much as 2 billion euros or $2.2 billion, include Mallinckrodt Plc and Per
6/30/15 - IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015
IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, today announced it has submitted its fifth abbreviated new drug application to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-seven. Jason Grenfell-Gardner, President and
6/30/15 - Inside The July/August Issue Of AARP Bulletin
WASHINGTON, June 30, 2015/ PRNewswire-USNewswire/ Social Security Celebrates 80 Years of Improving Lives: In a special in-depth feature, the July-August issue of AARP Bulletin provides an all-encompassing history of Social Security, then and now. From three reasons why Social Security will remain for the next generation to an insightful Q&A on th
6/30/15 - Market Research Rerports Inc: Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors
Market Research Reports, Inc. has announced the addition of "Competitor Analysis: Therapeutic Antibodies 2015- Biosimilars& Biosuperiors" research report to their website http://www.MarketResearchReports.com. This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars& Biosuperiors provides a competitor evaluation in the...
6/30/15 - Myanmar Healthcare Investment Summit & Myanmar Medical Pharma Cosmetics Expo by MiTA
MiTA providing Consulting for Trade& Investments in Medical& Health Care Sector in Myanmar since 2009.. Thein Thein Htay, Deputy Minister for Health, Myanmar, has kindly agreed to deliver Key Note Speech on "Medical& Health Care Sector Development in Myanmar Opportunities& Challenges". Myanmar Medical Conference will discuss about all important
6/30/15 - PRESS: Hikma, Mallinckrodt Bid For Boehringer Assets - Bloomberg
LONDON- Hikma Pharmaceuticals PLC is among bidders for Boehringer Ingelheim GmbH's Roxane Labs business in the US, Bloomberg reported citing people familiar with the matter. The report said that other potential buyers for the generic pharmaceutical unit, which may fetch as much as 2 billion euros or USD2.2 billion, include Mallinckrodt PLC and Perr
6/30/15 - Unified prescription form is launched [Daily Star, The (Lebanon)]
BEIRUT: The unified prescription form, which makes it easier for Lebanese patients to access inexpensive medicine, was launched Tuesday in what Prime Minister Tammam Salam called a "great national achievement." According to Health Minister Wael Abu Faour, generic drugs comprise just 13 percent of the pharmaceutical market in Lebanon. Head of Parlia
6/30/15 - WINNERS & LOSERS: Tesco And Sainsbury's Beaten By Morrisons
LONDON- The following stocks are amongst the biggest risers and fallers within the main London indices midday Tuesday.- FTSE 100 WINNERS- Hikma Pharmaceuticals, up 0.6%. The report said that other potential buyers for the generic pharmaceutical unit, which may fetch as much as EUR2 billion or USD2.2 billion, include Mallinckrodt and Per
6/29/15 - Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast
To access the webcast, go to Allergan's Investor Relations Web site at http://ir.allergan.com. Allergan plc, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model Growth Pharma. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervo
6/29/15 - Buchang to Increase Stake in Tianyin-Buchang Alliance
By a News Reporter-Staff News Editor at Pharma Business Week Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients updated that during the advanced stage of the discussions between Chengdu Tianyin...
6/29/15 - Global Next-generation Antibody Therapeutics Market Will Reach US$ 6,761.1 Million by 2022: Persistence Market Research
According to a new market report published by Persistence Market Research " Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022", the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at
6/29/15 - Global Next-generation Antibody Therapeutics Market Will Reach US$ 6,761.1 Million by 2022: Persistence Market Research [National News Agency (Lebanon)]
-According to a new market report published by Persistence Market Research "Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022", the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a
6/29/15 - Lannett Adds Albert Paonessa to Its Board [Health & Beauty Close - Up]
Lannett Company has appointed Albert R. Paonessa, III, to its Board of Directors, effective July 1. Adding his expertise will be a key strategic advantage for Lannett. " Lannett Company develops, manufactures, packages, markets and distributes generic pharmaceutical products for a range of medical indications.
6/29/15 - Leading Generics and Specialty Pharmaceutical Company Selects Revitas for Global Revenue Management
By a News Reporter-Staff News Editor at Pharma Business Week Revitas, Inc., the leader in revenue acceleration, announced that it has been selected by one of the largest generics and specialty pharmaceutical companies in the world to deliver an end-to-end revenue management solution and standardize the organization's worldwide operations onto a s
Articles(s): 1 - 25 of 47     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415